1. Protein Tyrosine Kinase/RTK
  2. FGFR

CH5183284 (Synonyms: Debio 1347)

Cat. No.: HY-19957 Purity: 99.17%
Data Sheet SDS Handling Instructions

CH5183284 is a selective and orally available FGFR1/2/3 inhibitor. The IC50 values of CH5183284 on the enzyme activity of FGFR1/2/3/4 were 9.3, 7.6, 22, and 290 nM, respectively.

For research use only. We do not sell to patients.
CH5183284 Chemical Structure

CH5183284 Chemical Structure

CAS No. : 1265229-25-1

Size Price Stock Quantity
10 mM * 1 mL in DMSO $121 In-stock
5 mg $110 In-stock
10 mg $190 In-stock
25 mg $330 In-stock
50 mg $500 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

CH5183284 is a selective and orally available FGFR1/2/3 inhibitor. The IC50 values of CH5183284 on the enzyme activity of FGFR1/2/3/4 were 9.3, 7.6, 22, and 290 nM, respectively. IC50 value: 9.3, 7.6, 22, and 290 nM (FGFR1/2/3/4) [1] Target: FGFR in vitro: The binding affinity (Kd) of CH5183284 for FGFR1, FGFR2, FGFR3, FGFR4, and KDR was 20, 20, 25, 740, and 960 nM, respectively (using the DiscoveRx panel). CH5183284 selectively inhibits FGFR1, FGFR2, and FGFR3 but does not inhibit kinase insert domain receptor (KDR) or other kinases. [1] CH5183284 shows antiproliferative activity against FGFR3-BAIAP2L1-positive cells only, including the bladder cancer cell line SW780, Rat-2_F3-B cells, and NIH-3T3 cells expressing FGFR3-BAIAP2L1, but not against NIH-3T3 cells expressing EML4-ALK (3T3_EML4-ALK) or HT1376 cells harboring WT FGFR. CH5183284/Debio 1347 induces apoptosis in SW780 and Rat-2_F3-B cells and suppresses FRS and ERK phosphorylation. [2] in vivo: CH5183284 shows significant antitumor activity against xenografts with FGFR genetic alterations. CH5183284 suppresses p-FGFR for at least 7 hours in SNU-16 xenograft tissue, as well as the downstream signaling, as indicated by a reduction in p-FRS, p-ERK, and p-S6. [1] CH5183284/Debio 1347 shows antitumor activity in SW780 and Rat-2_F3-B xenograft models, but not in WT FGFR HT1376 xenograft tumors. The downstream signals are suppressed in Rat-2_F3-B xenograft tumors treated by CH5183284/Debio 1347. [2]

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01948297 Debiopharm International SA Solid Tumours August 2013 Phase 1
NCT01948297 Debiopharm International SA Solid Tumours August 2013 Phase 1
View MoreCollapse
References
Molecular Weight

356.38

Formula

C₂₀H₁₆N₆O

CAS No.

1265229-25-1

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 31mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CH5183284
Cat. No.:
HY-19957
Quantity: